NCT06369467View on ClinicalTrials.gov

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

March 28, 2028

Study Completion Date

March 28, 2028

Conditions
Food Allergy
Interventions
DRUG

linvoseltamab

Administered by intravenous (IV) infusion

DRUG

dupilumab

Administered by subcutaneous (SC) injection

Trial Locations (7)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

19104

RECRUITING

The Children's Hospital of Philadelphia, Philadelphia

28027

RECRUITING

Clinica Universidad de Navarra - Madrid, Madrid

30322

RECRUITING

Emory University- Winship Cancer Institute, Atlanta

31008

RECRUITING

Clinica Universidad de Navarra- Pamplona, Pamplona

33613

RECRUITING

University of South Florida, Tampa

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY